DBV patch-based peanut therapy reports long-term desensitization results
Epicutaneous immunotherapy for peanut allergy in children showed long-term efficacy and safety, with 68.2% tolerating full food challenges after three years.
Epicutaneous immunotherapy for peanut allergy in children shows strong safety, convenience, and long-term efficacy, with 68.2% tolerating full food challenges after three years. Regulatory progress is advanced, and the THRIVE study aims to demonstrate lifelong desensitization in infants.Based on DB…